CEMIP promotes gefitinib resistance in lung cancer with EGFR-mutation possibly through forming a stable complex CEMIP/c-MYC
{{output}}
While gefitinib greatly improves the prognosis of lung cancer patients with epidermal growth factor receptor (EGFR) mutation, its inevitable resistance severely diminishes therapeutic efficacy. Cell migration-inducing protein (CEMIP) might interact with cellul... ...
